These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9848632)

  • 1. Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies.
    Sloand JA; Shelly MA; Erenstone AL; Schiff MJ; Talley TE; Dhakal MP
    Perit Dial Int; 1998; 18(5):522-7. PubMed ID: 9848632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis].
    Ficheux M; Cuny P; Lecouf A; Ryckelynck JP; Hurault de Ligny B; Lobbedez T
    Nephrol Ther; 2011 Dec; 7(7):558-61. PubMed ID: 21715234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.
    Auerbach M; Winchester J; Wahab A; Richards K; McGinley M; Hall F; Anderson J; Briefel G
    Am J Kidney Dis; 1998 Jan; 31(1):81-6. PubMed ID: 9428456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
    Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
    Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary edema: atypical anaphylactoid reaction to intravenous iron dextran.
    Freter S; Davidman M; Lipman M; Bercovitch D
    Am J Nephrol; 1997; 17(5):477-9. PubMed ID: 9382172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients.
    Sinha S; Chiu D; Peebles G; Swoboda P; Kolakkat S; Lamerton E; Fenwick S; Bhandari S; Kalra PA
    QJM; 2011 Mar; 104(3):221-30. PubMed ID: 20956457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients.
    Fishbane S; Lynn RI
    Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease.
    Hood SA; O'Brien M; Higgins R
    Nephrol Nurs J; 2000 Feb; 27(1):41-2. PubMed ID: 10852689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of total dose infusion of iron dextran in iron deficiency anaemia.
    Reddy CM; Kathula SK; Ali SA; Bekal R; Walsh M
    Int J Clin Pract; 2008 Mar; 62(3):413-5. PubMed ID: 18005041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.
    Sepandj F; Jindal K; West M; Hirsch D
    Nephrol Dial Transplant; 1996 Feb; 11(2):319-22. PubMed ID: 8671786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients.
    Low CL; Bailie GR; Eisele G
    Ren Fail; 1997 Nov; 19(6):781-8. PubMed ID: 9415935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
    Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
    J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia.
    Dossabhoy NR; Turley S; Gascoyne R; Tapolyai M; Sulaiman K
    Ren Fail; 2014 Aug; 36(7):1033-7. PubMed ID: 24845687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment.
    Senger JM; Weiss RJ
    ANNA J; 1996 Jun; 23(3):319-23; discussion 324-5. PubMed ID: 8716991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease.
    Koutroubakis IE; Oustamanolakis P; Karakoidas C; Mantzaris GJ; Kouroumalis EA
    Dig Dis Sci; 2010 Aug; 55(8):2327-31. PubMed ID: 19834803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
    Park L; Uhthoff T; Tierney M; Nadler S
    Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total dose iron dextran infusion in cancer patients: is it SaFe2+?
    Gilreath JA; Stenehjem DD; Rodgers GM
    J Natl Compr Canc Netw; 2012 May; 10(5):669-76. PubMed ID: 22570295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin.
    Ahsan N; Groff JA; Waybill MA
    Adv Perit Dial; 1996; 12():161-6. PubMed ID: 8865893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of peritonitis in chronic peritoneal dialysis patients infused with intravenous iron dextran.
    Allen JR; Troidle LK; Juergensen PH; Kliger AS; Finkelstein FO
    Perit Dial Int; 2000; 20(6):674-8. PubMed ID: 11216558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.